Oppenheimer Reiterates Bullish View on Questcor Pharmaceuticals (QCOR) After Nephrologists Conversations
Tweet
Share
E-mailGet Alerts QCOR Hot Sheet
Price: $93.60 --0%
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Oppenheimer reiterated its Outperform rating and $56 price target on Questcor Pharmaceuticals (NASDAQ: QCOR) Tuesday following nephrologists calls, which yielded positive takeaways on the Acthar opportunity in NS.
"We had the opportunity to speak with six US-based nephrologists, who see a total of 775 NS patients, and all of whom have had experience with Acthar," the analyst notes. "Overall, we come away thinking the most significant headwind facing Acthar adoption remains physician awareness, which we expect to be addressed by an expanding sales force and publication of additional studies."
Despite concerns, Acthar reimbursement appears very strong the firm notes. "Notably, nephrologist experience with Acthar has been highly positive, with ~65-70% of the target patient population (IMN and FSGS) exhibiting complete remission."
For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.
Shares of Questcor Pharmaceuticals closed at $37.09 yesterday.
"We had the opportunity to speak with six US-based nephrologists, who see a total of 775 NS patients, and all of whom have had experience with Acthar," the analyst notes. "Overall, we come away thinking the most significant headwind facing Acthar adoption remains physician awareness, which we expect to be addressed by an expanding sales force and publication of additional studies."
Despite concerns, Acthar reimbursement appears very strong the firm notes. "Notably, nephrologist experience with Acthar has been highly positive, with ~65-70% of the target patient population (IMN and FSGS) exhibiting complete remission."
For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.
Shares of Questcor Pharmaceuticals closed at $37.09 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
